CoChat

A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome

Jensterle, Mojca, Kravos, Nika Aleksandra, Pfeifer, Marija, Kocjan, Tomaz, Janez, Andrej · 2015 · Hormones

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

Objective The long-acting glucagon-like peptide 1 receptor agonist liraglutide is linked to progressive and sustained weight loss in obese people with diabetes. However, its efficacy and safety in women with polycystic ovary syndrome (PCOS) has not yet been addressed.Design Thirty-two obese women (aged 27.6±7.2 years, BMI 39.5±6.2 kg/m(2)) with newly diagnosed PCOS were randomized to receive either liraglutide 1.2 mg QD sc (n=17) or metformin 1000 mg BID po (n=15) for 12 weeks; 28 patients completed the study (14 on liraglutide and 14 on metformin). The main outcome was change in body weight.Results Intention-to-treat analysis showed significant BMI (-0.98 kg/m(2); p<0.001), body weight (-2.52 kg; p<0.001), waist circumference (-3.38 cm; p<0.001) and whole-body fat mass (-1.26%; p<0.001) reduction in both treatment arms without significant differences between therapeutic groups. However, in a subgroup of patients (n=9) with insulin resistance (HOMA(IR) >2), severe obesity and higher odds ratio for the metabolic syndrome (OR=3.9), the patients fared much better with liraglutide than with metformin (mean BMI decreased 2.13 kg/m(2) vs. 0.62 kg/m(2), respectively).Conclusions Short-term liraglutide treatment was associated with significant weight loss in a subset of obese patients with newly diagnosed PCOS and a higher metabolic risk profile.

Overview

Integrity signals

Registry

Crossref · 10.1007/bf03401383

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 39 references

Research works printed but not linked: 1

  1. American Diabetes Association, 2013 Standards of Medical Care in Diabetes-2013. Diabetes Care 36: Suppl 1: 26–27.

Cited by

Metadata

Authors
Jensterle, M., Kravos, N. A., Pfeifer, M., Kocjan, T., & Janez, A.
Affiliations
Ljubljana University Medical Centre (SI)
Venue
Hormones
Published
2015-01
Volume
14
Issue
1
Pages
81-90
ISSN
  • 1109-3099 (ISSN-L)
  • 2520-8721
OpenAlex
W2330618995
Cited by
117
References
39
Citations by year
2026: 13 · 2025: 12 · 2024: 10 · 2023: 8 · 2022: 18 · 2021: 17 · 2020: 5 · 2019: 5 · 2018: 8 · 2017: 11 · 2016: 6 · 2015: 4
FWCI
11.02
Type
journal article
Language
en
Open access
closed
Locations
  • HORMONES (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
liraglutide, polycystic ovary syndrome, obesity, weight loss, GLP-1 receptor agonists, metformin, insulin resistance, metabolic syndrome, body mass index, waist circumference, fat mass
MeSH terms
Liraglutide, Adult, Blood Glucose, Body Weight, Female, Humans, Hypoglycemic Agents, Metformin, Obesity, Polycystic Ovary Syndrome, Weight Loss, Body Mass Index, Treatment Outcome, Incretins, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.